 Legend Biotech Corporations NASDAQ: LEGN collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare MHLW seeking approval for ciltacabtagene autoleucel cilta-cel. Cilta-cel is a B-cell maturation antigen BCMA-directed chimeric antigen receptor CAR-T cell therapy for relapsed or refractory multiple myeloma who have received at least three prior therapies. 